公开(公告)号：WO2016071693A1

公开(公告)日：2016-05-12

申请号：PCT/GB2015/053350

申请日：2015-11-05

Applicant: OPTIBIOTIX LIMITED

Inventor： O'HARA, Stephen Patrick

IPC: A23L29/20 ,  A23L29/244 ,  A23L33/00 ,  A23L33/135 ,  A23L33/16 ,  A23L33/20 ,  A23L33/21 ,  A61K31/736 ,  A23C9/123 ,  A23C9/154

CPC classification number: A61K45/06 ,  A23C9/1238 ,  A23C9/1307 ,  A23C9/1322 ,  A23C9/133 ,  A23C9/137 ,  A23C17/02 ,  A23C19/062 ,  A23L33/135 ,  A23L33/21 ,  A23L33/30 ,  A23V2002/00 ,  A23V2200/00 ,  A23V2200/30 ,  A23V2200/3202 ,  A23V2200/3204 ,  A23V2200/326 ,  A23V2200/3262 ,  A23V2200/328 ,  A23V2200/332 ,  A23V2250/1586 ,  A23V2250/5058

Abstract: The present invention relates to compositions for use and formulation as weight management products and in particular fermented dairy foodstuffs. The compositions generally comprise two or more of the following components: a) a microbiome modifying component; b) a satiety modifying component; and c) a metabolic modifying 5 component and at least one of the following: d) St reptococcus thermophilus CBS 139100 and L actobacillus delbrueckii subsp. bulgaricus CBS 139099 microbial strains or mutant strains or fragments or fractions thereof; e) a combination of Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus microbial strains which together, or individually, are capable of secreting polysaccharides having high levels of galactosamine 10 and no or low levels of rhamnose and glucuronic acid when grown on a dairy substrate; or f) polysaccharides formed of: i) 15 – 25 % galactosamine; ii) 45 – 60 % galactose; and iii) 20 – 30 % glucose. The compositions may also be useful in the management or treatment of obesity, elevated cholesterol, diabetes, hypertension or heart disease.

Abstract translation: 本发明涉及用作和配制作为重量管理产品，特别是发酵乳制食品的组合物。 组合物通常包含两种或更多种以下组分：a）微生物组织修饰组分; b）饱腹感修饰组件; 和c）代谢修饰5组分和以下至少一种：d）嗜热链球菌CBS 139100和德氏乳杆菌 保加利亚乳杆菌CBS 139099微生物菌株或突变菌株或其片段或级分; e）嗜热链球菌和德氏乳酸杆菌亚种的组合。 保加利亚微生物菌株一起或分别能够分泌具有高水平的半乳糖胺10的多糖，当在乳制品基质上生长时，没有或低水平的鼠李糖和葡萄糖醛酸; 或f）由以下物质形成的多糖：i）15-25％半乳糖胺; ii）45-60％半乳糖; 和iii）20-30％的葡萄糖。 组合物还可用于治疗或治疗肥胖症，升高的胆固醇，糖尿病，高血压或心脏病。

公开(公告)号：WO2016071504A1

公开(公告)日：2016-05-12

申请号：PCT/EP2015/075950

申请日：2015-11-06

Applicant: DUPONT NUTRITION BIOSCIENCES APS

Inventor： LARSEN, Morten Krog ,  CRAMER, Jacob Flyvholm ,  LABARGE, Jeremy ,  EISELE, Thomas ,  HANSEN KJER, Karina

IPC: A23C9/12 ,  A23C9/137 ,  A23L29/206 ,  A23L29/231 ,  A23L29/238 ,  A23L29/244 ,  A23L29/25 ,  A23L29/262 ,  A23L33/135

CPC classification number: A23L33/21 ,  A23C9/1206 ,  A23C9/1216 ,  A23C2220/202 ,  A23G9/38 ,  A23L33/135 ,  C12N9/2471 ,  C12Y302/01023

Abstract: A host cell capable of expressing a polypeptide having β-galactosidase and/or transgalactosylating activity and which host cell is modified to be cellulase, mannanase and pectinase deficient.

Abstract translation: 能够表达具有β-半乳糖苷酶和/或转半乳糖基化活性的多肽的宿主细胞，宿主细胞被修饰为纤维素酶，甘露聚糖酶和果胶酶缺陷型。

公开(公告)号：WO01060176A1

公开(公告)日：2001-08-23

申请号：PCT/EP2001/001600

申请日：2001-02-14

IPC: A23K1/16 ,  A23L29/244 ,  A61K31/733 ,  A61P1/00 ,  A61P3/00 ,  A61P3/06 ,  A61P19/08 ,  A61P19/10 ,  A61P35/00 ,  A61P37/04 ,  C08B37/18 ,  A23L1/0528

CPC classification number: A61K31/733 ,  A23L29/244

Abstract: The invention relates to novel inulin products and compositions thereof, to their manufacture, to their use for modifying and modulating the bacterial flora and the fermentation pattern of inulin in the large intestine of humans, mammals or other vertebrates, to their use for providing improved inulin-associated nutritional effects/benefits, as well as to their use for the manufacture of consumer products and compositions for providing said effects/benefits in healthy, disfunctioned and diseased humans, mammals and other vertebrates. The novel inulin products consist of a particular mixture of an easily fermentable inulin (EFI) component and a hardly fermentable inulin (HFI) component. The nutritional effects/benefits include dietary fibre effects, improved mineral absorption, particularly calcium and magnesium, bone mineral density increase, reduction of bone mineral density loss, modulation of lipid metabolism, stimulation of the immune system, and anti-cancer effects. The novel inulin products are particularly suitable for the manufacture of a composition or a medicament for preventing, for postponing and/or for treating osteoporosis in humans, particularly in post-menopausal women and elderly people.

Abstract translation: 本发明涉及新颖的菊粉产品及其组合物，用于其制造，用于修饰和调节人类，哺乳动物或其他脊椎动物大肠中菊糖的细菌菌群和发酵模式，用于提供改良的菊粉 相关的营养效果/益处，以及它们用于制造消费品和组合物的用途，用于在健康，失能和患病的人，哺乳动物和其他脊椎动物中提供所述效果/益处。 新颖的菊粉产品由容易发酵的菊粉（EFI）组分和几乎不可发酵的菊粉（HFI）组分的特定混合物组成。 营养效应/益处包括膳食纤维作用，改善矿物质吸收，特别是钙和镁，骨矿物质密度增加，骨矿物质密度损失减少，脂质代谢调节，免疫系统刺激和抗癌作用。 新颖的菊粉产品特别适用于制造用于预防，推迟和/或治疗人类，特别是在绝经后妇女和老年人中的骨质疏松症的组合物或药物。